{"id":63310,"date":"2026-04-16T17:34:31","date_gmt":"2026-04-16T09:34:31","guid":{"rendered":"https:\/\/flcube.com\/?p=63310"},"modified":"2026-04-16T17:34:32","modified_gmt":"2026-04-16T09:34:32","slug":"zai-lab-and-boehringer-ingelheim-partner-on-dll3-combination-therapy-for-neuroendocrine-cancers","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63310","title":{"rendered":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers"},"content":{"rendered":"\n<p><strong>Zai Lab<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ: ZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG: 9688<\/a>) and <strong>Boehringer Ingelheim (BI)<\/strong> have announced a strategic clinical collaboration to evaluate the combination of <strong>obrixtamig<\/strong>, BI&#8217;s <strong>DLL3\/CD3 bispecific T-cell engager<\/strong>, and <strong>zocilurtatug pelitecan (zoci)<\/strong>, Zai Lab&#8217;s <strong>DLL3-targeted antibody-drug conjugate (ADC)<\/strong>. The partnership will focus on a <strong>Phase Ib\/II clinical study<\/strong> assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-framework\">Clinical Development Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Combination Therapy<\/strong><\/td><td>Obrixtamig (DLL3\/CD3 bispecific T-cell engager) + Zocilurtatug pelitecan (DLL3-targeted ADC)<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase Ib\/II<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety, tolerability, and preliminary clinical activity<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Poorly differentiated neuroendocrine carcinoma (NEC) and extensive-stage small cell lung cancer (ES-SCLC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Patients with aggressive neuroendocrine cancers requiring more effective treatment options<\/td><\/tr><tr><td><strong>Study Sponsor<\/strong><\/td><td>Boehringer Ingelheim<\/td><\/tr><tr><td><strong>Drug Supply<\/strong><\/td><td>Zai Lab to provide zocilurtatug pelitecan clinical study drug<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profiles\">Asset Profiles<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-obrixtamig-boehringer-ingelheim\">Obrixtamig (Boehringer Ingelheim)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> DLL3\/CD3 bispecific T-cell engager<\/li>\n\n\n\n<li><strong>Target:<\/strong> Delta-like ligand 3 (DLL3), highly expressed in neuroendocrine tumors<\/li>\n\n\n\n<li><strong>Mode of Action:<\/strong> Redirects T-cells to DLL3-expressing tumor cells, inducing targeted cytotoxicity<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Clinical development phase with prior Phase I data demonstrating anti-tumor activity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-zocilurtatug-pelitecan-zai-lab\">Zocilurtatug Pelitecan (Zai Lab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Former Designation:<\/strong> ZL-1310<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> DLL3-targeted antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Topoisomerase I inhibitor linked to anti-DLL3 monoclonal antibody<\/li>\n\n\n\n<li><strong>Target:<\/strong> Same DLL3 antigen, but delivers cytotoxic payload directly to tumor cells<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Investigational asset with preclinical proof-of-concept established<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-innovation\">Scientific Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Targeting Approach:<\/strong> Simultaneous engagement of DLL3 through two distinct mechanisms may enhance anti-tumor efficacy while potentially overcoming resistance mechanisms<\/li>\n\n\n\n<li><strong>Complementary Mechanisms:<\/strong> T-cell redirection (obrixtamig) combined with direct cytotoxic payload delivery (zoci) creates multi-modal attack on DLL3-expressing tumors<\/li>\n\n\n\n<li><strong>High Unmet Need:<\/strong> Both poorly differentiated NEC and ES-SCLC represent aggressive malignancies with limited treatment options and poor survival outcomes<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Operational Responsibilities:<\/strong> Boehringer Ingelheim serves as study sponsor with oversight of day-to-day clinical operations<\/li>\n\n\n\n<li><strong>Asset Rights:<\/strong> Both parties retain full rights to their respective proprietary compounds<\/li>\n\n\n\n<li><strong>Resource Allocation:<\/strong> Efficient division of responsibilities leverages each company&#8217;s core competencies in global clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-therapeutic-significance\">Market Context &amp; Therapeutic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>DLL3 Target Prevalence:<\/strong> Expressed in >80% of SCLC and neuroendocrine carcinoma cases, making it an attractive therapeutic target<\/li>\n\n\n\n<li><strong>ES-SCLC Landscape:<\/strong> Limited second-line options with median overall survival of 6-8 months after first-line therapy failure<\/li>\n\n\n\n<li><strong>NEC Treatment Gap:<\/strong> Poorly differentiated NEC represents an orphan indication with no standardized treatment protocols beyond platinum-based chemotherapy<\/li>\n\n\n\n<li><strong>Combination Therapy Trend:<\/strong> Increasing focus on rational combinations targeting the same pathway through complementary mechanisms to maximize efficacy<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This collaboration represents a scientifically rational approach to addressing some of the most challenging cancers in oncology,&#8221; said Dr. Samantha Du, Founder, CEO, and Chairperson of Zai Lab. &#8220;By combining our DLL3-targeted ADC with Boehringer Ingelheim&#8217;s bispecific T-cell engager, we aim to deliver meaningful clinical benefit to patients with limited treatment options.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development plans, partnership implementation, and therapeutic potential. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and scientific uncertainties inherent in drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,390,869,868,413],"class_list":["post-63310","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-boehringer-ingelheim","tag-hkg-9688","tag-nasdaq-zlab","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI&#039;s DLL3\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab&#039;s DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63310\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers\" \/>\n<meta property=\"og:description\" content=\"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI&#039;s DLL3\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab&#039;s DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63310\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T09:34:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T09:34:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers\",\"datePublished\":\"2026-04-16T09:34:31+00:00\",\"dateModified\":\"2026-04-16T09:34:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310\"},\"wordCount\":523,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Boehringer Ingelheim\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63310#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63310\",\"name\":\"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-16T09:34:31+00:00\",\"dateModified\":\"2026-04-16T09:34:32+00:00\",\"description\":\"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI's DLL3\\\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab's DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\\\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63310\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63310#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers - Insight, China&#039;s Pharmaceutical Industry","description":"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI's DLL3\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab's DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63310","og_locale":"en_US","og_type":"article","og_title":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers","og_description":"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI's DLL3\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab's DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.","og_url":"https:\/\/flcube.com\/?p=63310","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T09:34:31+00:00","article_modified_time":"2026-04-16T09:34:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63310#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63310"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers","datePublished":"2026-04-16T09:34:31+00:00","dateModified":"2026-04-16T09:34:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63310"},"wordCount":523,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Boehringer Ingelheim","HKG: 9688","NASDAQ: ZLAB","Zai Lab"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63310#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63310","url":"https:\/\/flcube.com\/?p=63310","name":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-16T09:34:31+00:00","dateModified":"2026-04-16T09:34:32+00:00","description":"Zai Lab (NASDAQ: ZLAB, HKG: 9688) and Boehringer Ingelheim (BI) have announced a strategic clinical collaboration to evaluate the combination of obrixtamig, BI's DLL3\/CD3 bispecific T-cell engager, and zocilurtatug pelitecan (zoci), Zai Lab's DLL3-targeted antibody-drug conjugate (ADC). The partnership will focus on a Phase Ib\/II clinical study assessing the safety, tolerability, and preliminary clinical activity of this novel dual DLL3-targeting approach in patients with high unmet medical need.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63310#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63310"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63310#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab and Boehringer Ingelheim Partner on DLL3 Combination Therapy for Neuroendocrine Cancers"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63310"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63310\/revisions"}],"predecessor-version":[{"id":63313,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63310\/revisions\/63313"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}